Author: OurCrowd

Three Israeli MedTech companies offer major advances in tailor-made medicine Nobel laureate Aaron Ciechanover vividly remembers the day the first partial genome was published in April 2000. It was a landmark moment, heralding the promise of personalized medicine, tailor-made to individual patients. Today, scientists can sequence a whole genome “in no time,” and together with other scientific advances, they “have tools to profile the patient, to the very last detail, almost to the very last detail,” Ciechanover told a webinar on precision medicine hosted by OurCrowd and featuring three of its portfolio companies. “Now we can connect it also to the treatment, and we can monitor whether patients do respond to treatment, and how they respond to treatment, how they develop side effects,” says Ciechanover, winner of the 2004 Nobel prize for chemistry. “If you connect all these data, you are generating unbelievable predictive tools.’’ Ciechanover now serves as the scientific advisor to OncoHost, one of three OurCrowd startups discussing predictive diagnostics at the webinar: Sequentify, whose sample-processing technologies dramatically reduce the time and cost of next-generation DNA sequencing;...